Company / Cash & Equivalents
Arcadia Biosciences, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$259.0K
FY2025
5-year range
$259.0K / $28.7M
FY2021-FY2025
Trend
-93.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $29M in FY2021 to $259,000 in FY2025.
Based on SEC 10-K filings.
$259,000 in FY2025 with a 5-year CAGR of -55.0%.
Declined from $7M to $259,000 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -76.8%
- 5-Year CAGR
- -55.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcadia Biosciences, Inc.'s cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -55.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 93.9% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $259.0K | -93.9% |
| FY2024 | $4.2M | -34.9% |
| FY2023 | $6.5M | -68.4% |
| FY2022 | $20.6M | -28.0% |
| FY2021 | $28.7M | +104.3% |
| FY2020 | $14.0M | +66.8% |
| FY2019 | $8.4M | -7.8% |
| FY2018 | $9.1M | +353.3% |
| FY2017 | $2.0M | -91.6% |
| FY2016 | $24.0M | +44.7% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026